Bersanlimab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBersanlimab
Drug Alias NameBI-505
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionIntercellular adhesion molecule-1 inhibitors
TargetsIntercellular adhesion molecule-1
Therapy Area/IndicationsSmoldering Multiple MyelomaMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSweden +[4
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBioinvent International Ab
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBioinvent International Ab
Active IndicationsN/A
Inactive IndicationsSmoldering Multiple MyelomaMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A